| 4.04 -0.06 (-1.46%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.85  |
1-year : | 5.25 |
| Resists | First : | 4.15 |
Second : | 4.5 |
| Pivot price | 3.99 |
|||
| Supports | First : | 3.59 |
Second : | 2.99 |
| MAs | MA(5) : | 4.03 |
MA(20) : | 3.95 |
| MA(100) : | 3.87 |
MA(250) : | 3.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46.6 |
D(3) : | 45.4 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 5.63 | Low : | 0.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MYO ] has closed below upper band by 43.9%. Bollinger Bands are 40.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.21 - 4.24 | 4.24 - 4.26 |
| Low: | 3.95 - 3.97 | 3.97 - 3.99 |
| Close: | 4 - 4.04 | 4.04 - 4.08 |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Thu, 12 Sep 2024
Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly - Business Wire
Thu, 12 Sep 2024
Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly - StockTitan
Thu, 05 Sep 2024
Myomo to Participate in Two Investor Conferences in September - Business Wire
Thu, 05 Sep 2024
Myomo to Participate in Two Investor Conferences in September - StockTitan
Tue, 13 Aug 2024
Myomo secures new headquarters in Burlington - Investing.com
Sat, 10 Aug 2024
Myomo, Inc. (AMEX:MYO) Q2 2024 Earnings Call Transcript - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 27 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 47.9 (%) |
| Shares Short | 236 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.41 |
| Profit Margin | -42.5 % |
| Operating Margin | -39.9 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | -83.4 % |
| Qtrly Rev. Growth | 28 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.69 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -8.25 |
| PEG Ratio | 35.1 |
| Price to Book value | 9.61 |
| Price to Sales | 5.78 |
| Price to Cash Flow | -17.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|